October 20, 2025

Updated ASTRO-ASCO-SSO PMRT Guideline: Key Changes and Clinical Implications

New joint clinical practice guidelines from ASTRO, ASCO, and SSO, published in the Journal of Clinical Oncology, provide the most comprehensive update in a decade on postmastectomy radiation therapy (PMRT) for breast cancer.

Baptist Health South Florida

October 20, 2025

Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer

The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.

Dana-Farber

October 15, 2025

Dana-Farber Research News 10.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - September 30.

Dana-Farber

October 14, 2025

Roswell Park Offers Exclusive CAR T-Cell Clinical Trial for Patients with Advanced or Metastatic Hepatoma

 A new, first-in-humans clinical trial for hepatocellular carcinoma uses an “armored” CAR T-cell therapy designed to resist the hostile tumor microenvironment found in 77% of patients with this disease.

Roswell Park Comprehensive Cancer Center

October 14, 2025

FDA Approves Combination Regimen for Extensive-Stage SCLC

Lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) was approved for maintenance treatment of adults with extensive-stage s...

The ASCO Post

October 10, 2025

Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress

“This study makes clear what many of us in oncology have suspected: Prior authorization isn’t just an administrative hurdle for clinicians; it’s a hidden second job for patients,” noted investigators....

The ASCO Post

October 08, 2025

Risk vs. Benefit: Clinical Trial Aims to Identify Patients with Early-Stage NSCLC Who May Not Need Immunotherapy After Surgery

Many patients with early-stage non-small cell lung cancer (NSCLC) are treated post-surgery with the monoclonal antibody durvalumab (brand name Imfinzi) — an FDA-approved regimen.

Roswell Park Comprehensive Cancer Center

October 08, 2025

Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO

Chronic myeloid leukemia (CML) is one of the success stories among the hematologic malignancies. Now, with decades of data informing its management, it is time to change some of the practices to which...

The ASCO Post

October 08, 2025

Breast Cancer Research: Updates for 2025

Novel treatment protocols are demonstrating significant improvements in overall survival and progression-free survival for breast cancer patients while targeted therapies continue to expand treatment options

Baptist Health South Florida